Valens GroWorks Corp. (CSE:VGW)(CSE:VGW.CN)(the “Company“) is pleased to announce the completion, by the Regional Inspectorate of the Office of Controlled Substances of Health Canada, of their final inspection of wholly-owned subsidiary Valens Agritech’s (“VAL“) 17,000 square foot R&D facility located in Kelowna, British Columbia.
The inspection is the final stage required to achieve licensing under our application for a Controlled Drugs and Substances Dealer’s Licence to enable the cultivation and processing of marijuana (such as creating extracts or derivatives) for the purpose of research, for processing manufacturing derivatives, and for transporting product to other locations (including related packaging, possession, sale, delivery and research activities).
Final pre-inspection preparation included the installation of significant enhanced physical security measures, the establishment of specified record keeping procedures, and the engagement of a Qualified Person In Charge (QPIC).
The Company is therefore pleased to announce Dr. Yasantha Athukorala, Ph.D. as the QPIC for VAL, as well as VAL’s Chief Scientific Officer. Dr. Athukorala is an accomplished scientist with outstanding research and leadership skills and more than 7 years of experience investigating bioactive compounds from agricultural bio-resources. With a unique background of Biotechnology, Chemistry and Bio-resource Technology knowledge, Dr. Athukorala brings a demonstrated record of project and publication success, credited with discovering naturally-occurring bioactive compounds using enzymatic digestion, bioassay-guided extraction and fractionation procedures with potential commercial applications in food, health and bio-resource utilization industries.
Dave Gervais, President of VAL., stated, “We warmly welcome Dr. Athukorala to the Valens team as we gear up to commence operations pending receipt of Health Canada’s Dealer’s Licence approval. Yasantha is a dedicated and creative scientist with superb transdisciplinary communication, relationship-building and team leadership attributes, and will be supported by a fully qualified alternate QPIC as we ramp up operations”.
About Valens GroWorks Corp.
The Company recently completed the acquisition of Valens Agritech Ltd. (“VAL“). VAL is a biotechnology company based in the Okanagan Valley of British Columbia, focused on cannabis cultivation and research, with assets and improvements that include a state-of-the-art 17,000 square foot R&D facility located in Kelowna, British Columbia.
Post-licensing, Valens anticipates participation in clinical trial programs researching the efficacy of medical cannabis for certain indications, and will also be seeking to capture a broad spectrum of medical marijuana users, as well as recreational users once legalized, in pursuit of its farm to pharma objectives.
On behalf of the Board of Directors,
VALENS GROWORKS CORP.
Robert van Santen, Chief Executive Officer
Cautionary statements
This press release contains forward-looking information based on current expectations. Statements about the Company’s expectations are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Valens Groworks assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. We seek safe harbor.
For further information, please contact:
Greg Patchell
+1.250.860.8634

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less